Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is: Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer? Participants will be randomised to receive either trilaciclib or placebo.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony drobnokomórkowy rak płuca w ograniczonym stadium.
- •Całkowite wyzdrowienie po wcześniejszych operacjach usunięcia nowotworu.
- •Nowotwór, który można zmierzyć i ocenić.
- •Zgoda na udział w badaniu i podpisanie formularza świadomej zgody.
✗ Disqualifies
- •Drobnokomórkowy rak płuca w zaawansowanym stadium.
- •Czynna choroba serca.
- •Znana nadwrażliwość na Trilakcyib lub inne leki stosowane w tym badaniu (etopozyd, karboplatyna, cisplatyna).
- •Kobiety w ciąży lub karmiące piersią.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Pharmacosmos Investigational Site
Oakland, United States
Trial contact
Pharmacosmos A/S Clinical and non-clinical research
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.